-
FDA Grants ImmunityBio COMPANY IL-15 Super Agocizer N-803 Breakthrough Therapy Identification
Time of Update: 2020-06-07
today, ImmunityBio (http:// announced that the U.S FDA (http:// awarded its IL-15 super-exciting N-803 breakthrough therapy for use in combination with BCG to treat non-muscular leachate insin
-
BioMarin announces final positive results from the Global Phase III study of vosoritide's treatment of cartilage dysplasia
Time of Update: 2020-06-07
recently, BioMarin (http:// published the final positive results of the global Phase III study of Vosoritide (Vsolitide, BMN111) for the treatment of patients with cartilage dysplasia (achondropl
-
FDA approves Genetech's new anti-flu drug, Baloxavir marboxil, for extended indications
Time of Update: 2020-06-07
Today, Roche's Gene (http:// announced that it had approved an extended indication of its new anti-flu drug (http:// , http:// the FDA ( http:// Xofluza will be used to treat people 12 years
-
FDA approves expansion of Sanofi long-acting insulin glargine injection Toujeo
Time of Update: 2020-06-07
recently, the U.S FDA (http:// approved the extension of Sanofi 's (http:// 's long-acting insulin glargine injection Toujeo for the treatment of children and adolescents with type 1 diabetes ag
-
FDA grants F2G candidate drug olorofim breakthrough therapy
Time of Update: 2020-06-07
, F2G (http:// announced that the U.S FDA (http:// awarded its first -candidate drug (http:// olorofim breakthrough therapy for treatment of patients with invasive fungal infections Olorofim
-
CHMP recommends Cyramza (ramucirumab) and erlotinib combination therapy first-line treatment of NSCLC adult patients
Time of Update: 2020-06-07
recently, Eli Lilly announced that the European Medicines (http:// Administration (EMA http:// http:// ) recommended single anti- drug (http:// ) and tyrosine coenzyme inhibitors (TKIs) erlo
-
FDA accepts a biologic license application for AstraZeneca immunotherapy imfinzi (durvalumab)
Time of Update: 2020-06-07
Small cell lung cancer is a rapidly developing, invasive lung cancer that accounts for about 15% of all lung cancer cases About three-quarters of those with small cell lung cancer were diagnosed at
-
Weishi anti-epileptic new drug Perampanel (Weiketai) has been approved by the State Drug Administration
Time of Update: 2020-06-07
Recently, , Aisya's anti-epileptic new drug (http:// Perampanel(Weiketai) was approved by the State Drug Administration for the use of adults and children 12 years and older with partial seizures (
-
Her reached primary and secondary endpoints in the 3rd phase of the study of GnRH receptor antagonist relugolix
Time of Update: 2020-06-07
today, Myovant Sciences company (http:// announced that it has reached the primary and all critical secondary endpoints in the Phase 3 study HERO for the treatment of patients with advanced prost
-
Positive results in Phase IIb clinical trial struck by oral insulin innovation drug ORMD-0801
Time of Update: 2020-06-07
recently, (http:// ("Tianmai Bio"),) of Hefei Tianmai Biotech Development Limited Company ("Tianmai Bio") and Israel's Oramd Pharmaceutical (http://"Alamd") Company ("Oramd"), jointly develope
-
The main and secondary endpoints of the trial reached in Phase 3 clinical trials of the double inhibitor bimekizumab
Time of Update: 2020-06-07
today, UCB (UCB) company (http:// announced that its target of IL-17A and IL-17F, a dual inhibitor bimekizumab, has reached all major and minor ends of the trial in the phase 3 clinical trial (
-
FDA approves Foamix company Amzeeq for treatment of inflammatory lesions in acne patients
Time of Update: 2020-06-07
recently, Foamix Pharmaceuticals (http:// announced that the U.S FDA (http:// approved the company's Amzeeq (minocycline, formerly known as FMX101) for the treatment of inflammatory lesions (a
-
FDA accelerates approval of Vyondys 53 for treatment of Duchenne muscular dystrophy
Time of Update: 2020-06-07
today, the United States The FDA's (http:// announced the accelerated approval of The of Sarepta Therapeutics company (http:// of Vyo ndys 53 (golodirsen) for treatment of Duchenne muscular d
-
NMPA approves Mersa East Keytruda to treat metastatic squamous non-small cell lung cancer in combination with caplatinum or yew alcohol
Time of Update: 2020-06-07
today, the (http:// (MSD) of The OfMersannounc announced that China's National Drug Administration (NMPA) has approved the company's heavy-duty PD-1 inhibitor Keytruda, which is used in conjuncti
-
Jansen Pharmaceuticals submits 2 marketing authorization applications to EMA
Time of Update: 2020-06-07
recently, Johnson and Johnson's Janssen Pharmaceutical (http:// company, (http:// announced that it had submitted two marketing authorization applications (MAA) to the European (http:// Auth
-
Voclosporin with mycophenolic acid and low-dose steroids to treat lupus nephritis Phase 3 clinical trials reach major and secondary endpoints
Time of Update: 2020-06-07
Lupus nephritis is a sign of severe progression of SLE disease due to inflammation of the kidneys caused by systemic lupus erythematosus (SLE) Today, Aurinia Pharmaceuticals (http:// announced t
-
NMPA approves Roche Pharmaceuticals Padter ® united with Herceptin ® and Dossie Tatse for treatment of metastatic breast cancer patients
Time of Update: 2020-06-07
recently, the Roche Pharmaceutical (http:// announced in China that The National Medicines (http:// Supervision Authority (NMPA) has officially approved the first-line standard treatment plan
-
Kite filed a biologics license application for T-cell therapy KTE-X19 with the FDA
Time of Update: 2020-06-07
recently, Gilead Sciences' Kite Company (http:// announced that it had submitted a biologic license application (BLA) for the device-based antigen receptor (CAR) T-cell therapy KTE-X19 to the U.S
-
FDA approves Sanofi Fluzone ® High-Dose Quadrivalent's Application for A Supplemental Biologics License
Time of Update: 2020-06-07
recently, Sanofi announced that the u.S Food and Drug (http:// Administration http:// (http:// has approved a supplemental biologic license (sBLA) for fluzone ® High-priced, four-price influen
-
Roche launches new type A haemophilia drug Hemlibra (emicizumab)
Time of Update: 2020-06-07
recently, , a Japanese drug http:// maker controlled by Roche, announced that its wholly-owned subsidiary company in Taiwan, http:// , , had launched the new drug , http:// , to the market Abou
